Dr. David Weidig Addresses Discharge Planning Initiatives in Pulmonary Medicine
David Weidig, MD, System Director of Hospital Medicine, Aurora Medical Group, Milwaukee, WI, says that readmissions are not necessarily a failure of medical treatment, but a failure of psycologic and social support systems for the patient that are not addressed while the patient is hospitalized. Dr Weidig states that the Society of Hospital Medicine's Project BOOST is a program that will allow people to look at tools that address the risks and issues that are key factors in readmission.
This video was taken on May 19, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
Two new studies in The American Journal of Managed Care find that state Medicaid restrictions on access to newer antipsychotic drugs save little in the short run, and may cost more later when patients fail to stay on their medication, end up in the hospital, or both.
The 2014 Spring Managed Care Forum, held April 24-25 in Orlando, FL, will feature sessions and discussions on today’s most important topics in healthcare. The Forum includes members and executives from the American Association of Integrated Healthcare Delivery Systems (AAIHDS), the American Association of Managed Care Nurses (AAMCN), and the National Association of Managed Care Physicians (NAMCP). Check back here for continuing conference coverage, or you can sign up for our daily e-mail blasts on our registration page.
Drug giants AstraZeneca and Pfizer are working on a new clinical trial design, to be launched in Britain in July or August of this year, to include multiple drugs for evaluation in a single trial. This is expected to be both time and cost saving and could significantly hasten drug development.
Doctors should consider expensive new hepatitis C drugs for patients with advanced liver disease, including those awaiting transplants, but ask most others to wait for drugs in development, the Department of Veterans Affairs said Wednesday.
The world’s largest organization of cancer doctors plans to rate the cost effectiveness of expensive oncology drugs, and will urge physicians to use the ratings to discuss the costs with their patients.
A US Department of Health and Human Services (HHS) analysis determined that a new payment formula, which would reduce Medicaid reimbursement rates for generic prescription drugs, could save Medicaid up to $1.2 billion per year. So why are pharmacists and drug manufacturers pushing back?